VisaThera Research Private Limited
VisaThera Research Private Limited is delighted to announce the appointment of Prof. Asad U. Khan, PhD, FRSC (UK), FAMS, FBRS, FABS, as Advisor – Research & Development and Innovation.
Prof. Khan will play a key strategic role in shaping VisaThera’s R&D roadmap, mentoring scientific teams, and accelerating the translation of innovative discoveries into impactful healthcare solutions.
About Prof. Asad U. Khan
Prof. Asad U. Khan is an eminent microbiologist with over three decades of research experience in microbiology, antimicrobial resistance, and infection control. He has published more than 250 research articles in reputed peer-reviewed journals and is widely recognized for his pioneering contributions to infectious disease research.
Key contributions include:
- Antimicrobial Resistance & Superbugs – Known internationally for his work on NDM-4 and related superbugs.
- Translational Innovation – Developer of a patented laser-based photodynamic therapy (PDT) platform for diabetic foot ulcer (DFU) treatment, integrating a unique nano-composite with exceptional antimicrobial and tissue-regenerative potential.
- National & International Leadership – Served on several research committees, task forces, and innovation evaluation panels.
- Awards & Recognition – Recipient of numerous prestigious national and international awards, including recognition from the Hon’ble President of India.
Message from VisaThera Leadership
“We are honored to welcome Prof. Asad U. Khan as Advisor – R&D and Innovation at VisaThera. His outstanding track record in antimicrobial resistance, translational microbiology, and technology development perfectly aligns with our vision to build a deep-tech, science-first biotech company from India.”
Looking Ahead
With Prof. Khan’s association, VisaThera aims to:
- Expand its innovation pipeline in infectious disease therapeutics.
- Strengthen global collaborations.
- Build a robust ecosystem for IP-driven biotech innovation.